Regulatory FDA kicks off review of Roche’s Gazyva for wider lupus use PharmaphorumRoche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus.RegulatoryImmunology & InflammationRead full story pharminent April 21, 2026 (Last updated: April 21, 2026) Pharmaphorum Roche could be just months away from an FDA approval of Gazyva as the first anti-CD20 therapy for systemic lupus erythematosus. RegulatoryImmunology & InflammationRead full story Post navigation Previous: Pfizer and Astellas secure FDA priority review for Padcev MIBC combo therapyNext: Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026